SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics ($CAPR) is trending due to positive Phase 3 trial results for its DMD treatment, deramiocel, sparking optimism for FDA approval. The stock saw a massive surge, leading to discussions about potential short squeezes and long-term value, with some community members predicting prices well beyond current levels. Bullish sentiment is fueled by the potential for buyout offers and the prospect of deramiocel becoming a significant treatment option, though some caution against short-term volatility.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd is actively chanting the ticker $CAW and expressing excitement, referring to themselves as a strong, organic community. The token's multichain functionality and deflationary burn mechanism are key talking points, with some suggesting it is the leading meme coin on the Cronos chain.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as investors discuss its potential following recent earnings and its position in the automation and AI space, with some highlighting its profitability and partnerships. Community members are debating whether the company is undervalued compared to its peers, while others are analyzing its growth trajectory and market adoption. Discussions also include the impact of potential short squeezes and the company's long-term prospects within the evolving AI landscape.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses potential breakouts and its established role as 'digital silver'. The conversation highlights its reliable payment network and the possibility of a Litecoin ETF, sparking interest in its utility and long-term potential. Some users are also closely watching the LTCBTC chart for bullish signals.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as community members discuss the potential impact of Marvell's acquisition of Celestial AI, a key partner utilizing POET's optical interposer technology. Community members speculate on potential increased demand and a possible acquisition, with many viewing the recent price action as an opportunity. Some believe the acquisition validates POET's technology and could lead to significant growth in the AI interconnect market.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending as community members discuss the potential impact of the 'crow with knife' meme coin ($CAW) on the Cronos chain. Bullish sentiment points to $CRO's underlying technology and real-world use cases, while some traders express frustration with price action relative to Bitcoin's movements. Recent partnerships and developments within the Crypto.com ecosystem may also be contributing to increased attention.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending as investors react to earnings and a new partnership with Palantir, focusing on AI-driven cloud solutions. The community is debating whether the earnings justify the valuation and discussing the potential impact of the Palantir collaboration on the company's growth trajectory. SNOW's performance is also being compared to competitors in the data and AI space, such as Databricks and Microsoft.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to significant price movement and high trading volume, sparking discussions about potential short squeezes and the company's fundamentals. Community chatter includes both bullish speculation for continued upward momentum and bearish concerns regarding possible dilution and reverse splits. The stock's volatile behavior is drawing attention, with some comparing it to other high-flying tickers.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

AI's stock is trending amid discussions around its recent earnings and future prospects, with some traders pointing to its high short interest as a potential catalyst for a meme-driven rally. Community sentiment is mixed, with debates focusing on the company's turnaround potential under its new CEO and its positioning within the competitive AI landscape. Some investors are closely watching for potential government contracts, as well as any partnership developments.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is trending as the community discusses its recent price movements and potential for further gains, with some highlighting its relative strength compared to other cryptocurrencies. Recent news includes BlackRock's BUIDL fund expanding to BNB Chain and YZi Labs pushing for board changes at a BNB treasury firm, influencing community sentiment. Some users suggest it's a good long-term hold, while others express concerns about centralization and potential manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avadel Pharmaceuticals (NASDAQ:AVDL) Trading Down 6.9% - Should You Sell?

Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Down 6.9% - Time to Sell...

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal

Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.

Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-DENN, ELST, AVDL, and CADE

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-DENN, ELST, AVDL, and CADE $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-DENN...

Alkermes Raises Offer To Acquire Avadel In Deal Worth Up To $22.50 Per Share

(RTTNews) - Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said they have agreed to the terms of an increased offer under which Alkermes will acquire Avadel for up to $22.50...

<ul class="summary-bullets"><li>The revised transaction has been approved by the board of directors of both Alkermes and Avadel.</li><li>The transaction is expected to close in the first quarter of 2026.</li></ul>Alkermes plc (ALKS) on Wednesday announced an increased offer to acquire Avadel Pharmaceuticals plc (AVDL) after the latter received another acquisition proposal from Lundbeck.Alkermes had decided to acquire all outstanding ordinary shares of Avadel for up to $20 per share in October. However, Avadel <a href="https://stocktwits.com/news-articles/markets/equity/avadel-gets-acquisition-proposal-from-lundbeck-weeks-after-inking-agreement-with-alkermes/cLPQetHRE4T">said</a> last week that it has received an unsolicited proposal from H. Lundbeck A/S to acquire the drugmaker for up to $23 per share, pressuring Alkermes to up their offer.<h2 class="st-heading-2">Terms Of New Deal</h2>Alkermes will<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-302619905.html"> now acquire</a> Avadel for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share. The additional cash payment will be awarded if the U.S. Food and Drug Administration approves Avadel’s Lumryz for the treatment of idiopathic hypersomnia in adults by the end of 2028.The increased offer values Avadel at up to approximately $2.37 billion. The revised transaction has been approved by the board of directors of both Alkermes and Avadel, the companies said. The transaction is expected to close in the first quarter of 2026.The Avadel board of directors now believes that the Lundbeck proposal no longer constitutes a superior proposal. While Lundbeck proposed to buy Avadel for up to $23, higher than Alkermes’ increased offer of $22.5, the terms of the CVR in Alkermes’s increased offer are superior to the terms of the CVR in Lundbeck's proposal, the board noted. The terms of the CVR in the Lundbeck proposal are unlikely to be achieved, they added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/AVDL">AVDL shares</a> traded 0.5% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around AVDL fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.AVDL shares have more than doubled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/elbit-systems-grabs-fresh-210-m-israeli-defense-order-on-top-of-a-record-backlog/cLPoeBRREB5">Elbit Systems' Grabs Fresh $210M Israeli Defense Order On Top Of A Record Backlog</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, an Avadel logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge 

Alkermes will now acquire Avadel for total transaction consideration of up to $22.50 per share. 

Equity

Alkermes will now acquire Avadel for total transaction consideration of up to $22.50 per share. 


Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc PR Newswire DUBLIN, Nov. 19, 2025 NOT FOR...

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal

AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives Consensus Rating of "Reduce" from Brokerages

Shares of Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Get Free Report) have received an average recommendation of "Reduce" from the thirteen brokerages that are currently covering the firm...

Atria Investments Inc Reduces Stock Position in Avadel Pharmaceuticals PLC. $AVDL

Atria Investments Inc cut its stake in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) by 51.3% in the second quarter, according to its most recent Form 13F filing with the Securities...

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

AVDL
Avadel Pharm Sp ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AVDL News

AVDLAvadel Pharm Sp ADR